Potential for antimicrobial resistance in Chlamydia pneumoniae
- PMID: 10839739
- DOI: 10.1086/315608
Potential for antimicrobial resistance in Chlamydia pneumoniae
Abstract
Antimicrobial resistance has not yet been described in wild type Chlamydia pneumoniae isolates, nor has selective emergence of resistance in the laboratory after exposure to subinhibitory concentrations of antibiotic. However, few clinical isolates have been tested for resistance, especially strains with resistance phenotypes (i.e., those associated with clinical failure or persistence). More widespread testing of such strains is needed. Further understanding of antimicrobial resistance in chlamydiae would benefit from the development of standardized methods. Further, more physiologic testing methodologies that more closely mimic the chronic intracellular infection usually being treated in vivo would be of value. Animal models demonstrate persistence of C. pneumoniae after antimicrobial therapy and could be used to better define the clinical correlates of in vitro testing.
Similar articles
-
Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.J Infect Dis. 2005 Mar 15;191(6):917-23. doi: 10.1086/428290. Epub 2005 Feb 11. J Infect Dis. 2005. PMID: 15717267 Review.
-
[Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].Acta Med Croatica. 2004;58(4):329-33. Acta Med Croatica. 2004. PMID: 15700690 Review. Croatian.
-
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.J Antimicrob Chemother. 2003 Sep;52(3):497-9. doi: 10.1093/jac/dkg371. Epub 2003 Aug 13. J Antimicrob Chemother. 2003. PMID: 12917246
-
Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment.J Infect Dis. 2000 Jun;181 Suppl 3:S394-401. doi: 10.1086/315602. J Infect Dis. 2000. PMID: 10839723 Review.
-
The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.J Antimicrob Chemother. 2004 Jul;54(1):281-2. doi: 10.1093/jac/dkh304. Epub 2004 Jun 9. J Antimicrob Chemother. 2004. PMID: 15190026 No abstract available.
Cited by
-
From coughs to complications: the story of Chlamydia pneumoniae.J Med Microbiol. 2025 Apr;74(4):002006. doi: 10.1099/jmm.0.002006. J Med Microbiol. 2025. PMID: 40279169 Free PMC article. Review.
-
Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC.Antimicrob Agents Chemother. 2005 Nov;49(11):4455-64. doi: 10.1128/AAC.49.11.4455-4464.2005. Antimicrob Agents Chemother. 2005. PMID: 16251283 Free PMC article.
-
Host cell responses to Chlamydia pneumoniae in gamma interferon-induced persistence overlap those of productive infection and are linked to genes involved in apoptosis, cell cycle, and metabolism.Infect Immun. 2007 Jun;75(6):2853-63. doi: 10.1128/IAI.01045-06. Epub 2007 Mar 12. Infect Immun. 2007. PMID: 17353287 Free PMC article.
-
In vitro inhibitory effects of hinokitiol on proliferation of Chlamydia trachomatis.Antimicrob Agents Chemother. 2005 Jun;49(6):2519-21. doi: 10.1128/AAC.49.6.2519-2521.2005. Antimicrob Agents Chemother. 2005. PMID: 15917561 Free PMC article.
-
Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.Antimicrob Agents Chemother. 2003 Feb;47(2):636-42. doi: 10.1128/AAC.47.2.636-642.2003. Antimicrob Agents Chemother. 2003. PMID: 12543671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical